| Allena Pharmaceuticals Inc (ALNA) | |||
|---|---|---|---|
| 0.075 0.002 (3.16%) | 09-07 16:00 | ||
| Open: | 0.0641 | Pre. Close: | 0.0727 |
| High: | 0.1459 | Low: | 0.06 |
| Volume: | 252,311,606 | Market Cap: | 0(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |   |
| Target: | Six months: 0.11 One year: 0.17 |
| Support: | Support1: 0.01 Support2: 0.01 |
| Resistance: | Resistance1: 0.09 Resistance2: 0.15 |
| Pivot: | 0.07 |
| Moving Averages: | MA(5): 0.08 MA(20): 0.06 MA(100): 0.09  MA(250): 0.24 |
| MACD: | MACD(12,26): 0.01 Signal(12,26,9): 0.01 |
| %K %D: | %K(14,3): 47.01 %D(3): 47.01 |
| RSI: | RSI(14): 80.52 |
| 52-Week: | High: Low: Change(%): -89.9 |
| Average Vol(K): | 3-Month: 68148 10-Days: 261996 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 0.15 - 0.151 | 0.151 - 0.151 |
| Low: | 0.059 - 0.06 | 0.06 - 0.06 |
| Close: | 0.079 - 0.08 | 0.08 - 0.081 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ALNA ] has closed below upper band by 43.3%. Bollinger Bands are 21.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
| Company profile |
|---|
| Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Capital Market | |
| Sector: Healthcare | |
| Industry: Biotechnology | |
| Shares Out. (M) | 85.37 |
| Shares Float (M) | 106.61 |
| % Held by Insiders | 1.15 |
| % Held by Institutions | 7.59 |
| Shares Short (K) | 8590 |
| Shares Short Prior Month (K) | 2560 |
| Stock Financials | |
|---|---|
| EPS | -1.010 |
| Book Value (p.s.) | 0.440 |
| Profit Margin | |
| Operating Margin | |
| Return on Assets (ttm) | -96.0 |
| Return on Equity (ttm) | -278.1 |
| Qtrly Rev. Growth | |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | -0.555 |
| Qtrly Earnings Growth | |
| Operating Cash Flow (M) | -55.68 |
| Levered Free Cash Flow (M) | -37.70 |
| Stock Valuation | |
|---|---|
| PE Ratio | -0.07 |
| PEG Ratio | |
| Price to Book value | 0.17 |
| Price to Sales | |
| Price to Cash Flow | -0.11 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | |
